dsip-texas Texas DPS committed to protecting and serving Texas in 2026 DSIP-Delta - Research Peptide

lowest tolerated dose Phase Step 2 Weeks Weeks 5-8 Cagrilintide Dose 0.5 mg/week Purpose Dose escalation Phase Step 3 Weeks Weeks 9-12 Cagrilintide Dose 1.0 mg/week Purpose GI side effects often peak here Phase Step 4 Weeks Weeks 13-16 Cagrilintide Dose 1.7 mg/week Purpose Approaching maintenance Phase Maintenance Weeks Weeks 17+ Cagrilintide Dose 2.4 mg/week Purpose Target dose used in late-stage study protocols Each step lasts 4 weeks

General wellness and longevity Some researchers use GHK-CU as a general longevity compound based on its broad gene expression effects favoring tissue maintenance and repair

The GHK-Cu literature is among the most robust of any synthetic or naturally occurring cosmetic peptide, with published data from independent research groups across multiple countries

In laboratory settings, Cagrilintide (CAGRI) is explored for amylin-receptor signaling, food-intake regulation, post-meal glucose response, and combination models